Contineum Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Contineum Therapeutics, Inc. (CTNM) reported Increase Decrease In Operating Lease Liability of -$1.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-07-30
- Contineum Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$380.00K.
- Contineum Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$1.30M.
- Contineum Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$495.00K, a 1867.86% decline year-over-year.
- Contineum Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$257.00K, a 2076.92% decline year-over-year.
- Contineum Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$1.26M, a 2010.61% decline from fiscal 2024.
- Contineum Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was $66.00K.
- Contineum Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$1.33M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$380.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$1.68M 10-Q · filed 2026-07-30 | -$2.17M derived: sum of 3 quarters · filed 2026-07-30 | -$2.43M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | -$1.30M 10-Q · filed 2026-05-05 | -$1.79M derived: sum of 2 quarters · filed 2026-05-05 | -$2.05M derived: sum of 3 quarters · filed 2026-05-05 | -$2.30M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | -$495.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$752.00K derived: sum of 2 quarters · filed 2026-03-05 | -$1.00M derived: sum of 3 quarters · filed 2026-07-30 | -$1.26M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$257.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$509.00K derived: sum of 2 quarters · filed 2026-07-30 | -$766.00K 10-Q · filed 2025-10-30 | -$738.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$252.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | -$509.00K 10-Q · filed 2026-07-30 | -$481.00K derived: sum of 3 quarters · filed 2026-07-30 | -$468.00K derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | -$257.00K 10-Q · filed 2026-05-05 | -$229.00K derived: sum of 2 quarters · filed 2026-05-05 | -$216.00K derived: sum of 3 quarters · filed 2026-05-05 | -$203.00K derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $41.00K derived: sum of 2 quarters · filed 2026-03-05 | $54.00K derived: sum of 3 quarters · filed 2026-03-05 | $66.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $26.00K derived: sum of 2 quarters · filed 2025-10-30 | $38.00K 10-Q · filed 2025-10-30 | -$511.00K derived: sum of 4 quarters · filed 2025-10-30 |
| 2024-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $25.00K 10-Q · filed 2025-08-05 | -$524.00K derived: sum of 3 quarters · filed 2025-08-05 | -$786.00K derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $12.00K 10-Q · filed 2025-05-14 | -$537.00K derived: sum of 2 quarters · filed 2025-05-14 | -$799.00K derived: sum of 3 quarters · filed 2025-05-14 | -$1.05M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$549.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$811.00K derived: sum of 2 quarters · filed 2025-03-06 | -$1.06M derived: sum of 3 quarters · filed 2025-03-06 | -$1.33M 10-K · filed 2025-03-06 |
| 2023-09-30 | -$262.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$516.00K derived: sum of 2 quarters · filed 2024-11-06 | -$779.00K 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$254.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$517.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$263.00K 10-Q · filed 2024-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |